Abstract
Standardized reporting is more and more routinely implemented in clinical practice, and such structured reports have a major impact on a large variety of medical fields, such as laboratory medicine, pathology, and, recently, radiology. Notably, the field of nuclear medicine is constantly evolving as novel radiotracers for numerous clinical applications are developed. Thus, framework systems for standardized reporting in this field may increase clinical acceptance of new radiotracers, allow for inter- and intracenter comparisons for quality assurance, and be used in global multicenter studies to ensure comparable results and enable efficient data abstraction. In the last couple of years, several standardized framework systems for PET radiotracers with potential theranostic applications have been proposed. These include systems for prostate-specific membrane antigen–targeted PET agents to diagnose and treat prostate cancer, and systems for somatostatin receptor–targeted PET agents to diagnose and treat neuroendocrine neoplasia. In the present review, the framework systems for these 2 types of cancer will be briefly introduced, followed by an overview of their advantages and limitations. In addition, potential applications will be defined, approaches to validate such concepts will be proposed, and future perspectives will be discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 577-584 |
| Number of pages | 8 |
| Journal | Journal of Nuclear Medicine |
| Volume | 60 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 1 2019 |
| Externally published | Yes |
Fingerprint
Keywords
- Ga-DOTANOC
- Ga-DOTATATE
- Ga-DOTATOC
- Neuroendocrine neoplasia
- Prostate cancer
- Somatostatin receptor
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
Novel structured reporting systems for theranostic radiotracers. / Werner, Rudolf A.; Bundschuh, Ralph A.; Bundschuh, Lena; Fanti, Stefano; Javadi, Mehrbod S.; Higuchi, Takahiro; Weich, Alexander; Pienta, Kenneth J.; Buck, Andreas K.; Pomper, Martin G.; Gorin, Michael A.; Herrmann, Ken; Lapa, Constantin; Rowe, Steven P.
In: Journal of Nuclear Medicine, Vol. 60, No. 5, 01.05.2019, p. 577-584.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Novel structured reporting systems for theranostic radiotracers
AU - Werner, Rudolf A.
AU - Bundschuh, Ralph A.
AU - Bundschuh, Lena
AU - Fanti, Stefano
AU - Javadi, Mehrbod S.
AU - Higuchi, Takahiro
AU - Weich, Alexander
AU - Pienta, Kenneth J.
AU - Buck, Andreas K.
AU - Pomper, Martin G.
AU - Gorin, Michael A.
AU - Herrmann, Ken
AU - Lapa, Constantin
AU - Rowe, Steven P.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Standardized reporting is more and more routinely implemented in clinical practice, and such structured reports have a major impact on a large variety of medical fields, such as laboratory medicine, pathology, and, recently, radiology. Notably, the field of nuclear medicine is constantly evolving as novel radiotracers for numerous clinical applications are developed. Thus, framework systems for standardized reporting in this field may increase clinical acceptance of new radiotracers, allow for inter- and intracenter comparisons for quality assurance, and be used in global multicenter studies to ensure comparable results and enable efficient data abstraction. In the last couple of years, several standardized framework systems for PET radiotracers with potential theranostic applications have been proposed. These include systems for prostate-specific membrane antigen–targeted PET agents to diagnose and treat prostate cancer, and systems for somatostatin receptor–targeted PET agents to diagnose and treat neuroendocrine neoplasia. In the present review, the framework systems for these 2 types of cancer will be briefly introduced, followed by an overview of their advantages and limitations. In addition, potential applications will be defined, approaches to validate such concepts will be proposed, and future perspectives will be discussed.
AB - Standardized reporting is more and more routinely implemented in clinical practice, and such structured reports have a major impact on a large variety of medical fields, such as laboratory medicine, pathology, and, recently, radiology. Notably, the field of nuclear medicine is constantly evolving as novel radiotracers for numerous clinical applications are developed. Thus, framework systems for standardized reporting in this field may increase clinical acceptance of new radiotracers, allow for inter- and intracenter comparisons for quality assurance, and be used in global multicenter studies to ensure comparable results and enable efficient data abstraction. In the last couple of years, several standardized framework systems for PET radiotracers with potential theranostic applications have been proposed. These include systems for prostate-specific membrane antigen–targeted PET agents to diagnose and treat prostate cancer, and systems for somatostatin receptor–targeted PET agents to diagnose and treat neuroendocrine neoplasia. In the present review, the framework systems for these 2 types of cancer will be briefly introduced, followed by an overview of their advantages and limitations. In addition, potential applications will be defined, approaches to validate such concepts will be proposed, and future perspectives will be discussed.
KW - Ga-DOTANOC
KW - Ga-DOTATATE
KW - Ga-DOTATOC
KW - Neuroendocrine neoplasia
KW - Prostate cancer
KW - Somatostatin receptor
UR - http://www.scopus.com/inward/record.url?scp=85065542102&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065542102&partnerID=8YFLogxK
U2 - 10.2967/jnumed.118.223537
DO - 10.2967/jnumed.118.223537
M3 - Article
C2 - 30796171
AN - SCOPUS:85065542102
VL - 60
SP - 577
EP - 584
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
SN - 0161-5505
IS - 5
ER -